Femasys (FEMY) announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with leading distributor Kebomed. Following the Company’s recent entry into Spain, this order marks continued progress in expanding FemBloc’s presence across key European markets and reflects growing international momentum for this innovative, non-surgical permanent contraceptive solution.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys Secures $12 Million Through Private Placement
- Femasys Receives FDA Approval for FemBloc Trial
- Femasys secures FDA approval to advance final FemBloc trial phase
- Femasys, Inc. Advances Non-Surgical Birth Control with FemBloc Study
- Femasys announces initiation of post-market surveillance study for FemBloc